1877.HK - Shanghai Junshi Biosciences Co., Ltd.

HKSE - HKSE Delayed price. Currency in HKD

Shanghai Junshi Biosciences Co., Ltd.

Building 7
15th Floor No.6, Lane 100, Pingjiaqiao Road Pudong New Area
Shanghai 200126
86 21 6105 8800

Full-time employees2,961

Key executives

NameTitlePayExercisedYear born
Mr. Jun XiongExec. ChairmanN/AN/A1974
Dr. Ning LiCo-CEO, GM & Exec. DirectorN/AN/A1962
Mr. Cong LiCo-CEO & Exec. DirectorN/AN/A1964
Mr. Baohong XuFinancial DirectorN/AN/A1979
Dr. Hui FengChief Operations Officer & Exec. DirectorN/AN/A1977
Mr. Zhuobing ZhangDeputy GM & Exec. DirectorN/AN/A1968
Dr. Sheng YaoSr. VP & Exec. DirectorN/AN/A1976
Ms. Lu YuanAssistant to GM & Chief of Internal Audit DepartmentN/AN/A1982
Mr. Gang WangChief Quality Officer & Sr. VP of Industry AffairsN/AN/A1957
Mr. Qian WeiChief Commercial OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; and Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody, as well as collaboration with Dr. Reddy's Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Corporate governance

Shanghai Junshi Biosciences Co., Ltd.’s ISS governance QualityScore as of 1 June 2023 is 6. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.